UK medical cannabis registry: an updated analysis of clinical outcomes of cannabis-based medicinal products for inflammatory bowel disease.

IF 3.8 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-12-17 DOI:10.1080/17474124.2024.2443574

Aashray Gupta, Simon Erridge, Vivian Graf, Monica Kelada, Lara Bapir, Naveen Jesuraj, John Warner-Levy, Evonne Clarke, Katy McLachlan, Ross Coomber, James J Rucker, Michael W Platt, Mikael H Sodergren

{"title":"UK medical cannabis registry: an updated analysis of clinical outcomes of cannabis-based medicinal products for inflammatory bowel disease.","authors":"Aashray Gupta, Simon Erridge, Vivian Graf, Monica Kelada, Lara Bapir, Naveen Jesuraj, John Warner-Levy, Evonne Clarke, Katy McLachlan, Ross Coomber, James J Rucker, Michael W Platt, Mikael H Sodergren","doi":"10.1080/17474124.2024.2443574","DOIUrl":null,"url":null,"abstract":"Background: Treatments for inflammatory bowel disease (IBD) remain limited, and cannabis-based medicinal products (CBMPs) provide promise in addressing inflammation and pain. However, long-term data on CBMP efficacy in IBD is scarce. This study examines health-related quality of life (HRQoL) changes in IBD patients treated with CBMPs.Research design and methods: Patients with IBD were identified from the UK Medical Cannabis Registry. Primary outcomes were changes in the short IBD questionnaire (SIBDQ), EQ-5D-5 L, single-item sleep quality scale (SQS) and generalized anxiety disorder-7 (GAD-7), from baseline to 18-months after CBMP treatment started. Secondary outcomes were adverse event prevalence.Results: Analysis of 116 patients with IBD, included 94 males (81.03%) with a mean age of 39.52 ± 9.12 years. There were improvements in the SIBDQ, GAD-7, SQS and EQ-5D-5 L Index (p < 0.001). At 18-months, 30 (25.86%) patients achieved a minimal clinically important difference (MCID) in the SIBDQ. Patients with severe baseline anxiety and above-median THC doses were more likely to achieve this MCID (p < 0.050). Twenty (17.24%) patients reported 155 (133.62%) adverse events.Conclusions: CBMP treatment was associated with improvement in IBD-specific outcomes in patients and general HRQoL over 18-months. However, causation cannot be inferred. Hence, randomized controlled trials are still required.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2024.2443574","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Treatments for inflammatory bowel disease (IBD) remain limited, and cannabis-based medicinal products (CBMPs) provide promise in addressing inflammation and pain. However, long-term data on CBMP efficacy in IBD is scarce. This study examines health-related quality of life (HRQoL) changes in IBD patients treated with CBMPs.

Research design and methods: Patients with IBD were identified from the UK Medical Cannabis Registry. Primary outcomes were changes in the short IBD questionnaire (SIBDQ), EQ-5D-5 L, single-item sleep quality scale (SQS) and generalized anxiety disorder-7 (GAD-7), from baseline to 18-months after CBMP treatment started. Secondary outcomes were adverse event prevalence.

Results: Analysis of 116 patients with IBD, included 94 males (81.03%) with a mean age of 39.52 ± 9.12 years. There were improvements in the SIBDQ, GAD-7, SQS and EQ-5D-5 L Index (p < 0.001). At 18-months, 30 (25.86%) patients achieved a minimal clinically important difference (MCID) in the SIBDQ. Patients with severe baseline anxiety and above-median THC doses were more likely to achieve this MCID (p < 0.050). Twenty (17.24%) patients reported 155 (133.62%) adverse events.

Conclusions: CBMP treatment was associated with improvement in IBD-specific outcomes in patients and general HRQoL over 18-months. However, causation cannot be inferred. Hence, randomized controlled trials are still required.

查看原文本刊更多论文

背景：炎症性肠病（IBD）的治疗方法仍然有限，而大麻类药用产品（CBMPs）有望解决炎症和疼痛问题。然而，有关 CBMP 在 IBD 中疗效的长期数据却很少。本研究探讨了接受 CBMPs 治疗的 IBD 患者与健康相关的生活质量（HRQoL）变化：研究设计：从英国医用大麻登记处确定 IBD 患者。主要结果是 IBD 短问卷（SIBDQ）、EQ-5D-5 L、单项睡眠质量量表（SQS）和广泛性焦虑症-7（GAD-7）从基线到 CBMP 治疗开始后 18 个月的变化。次要结果为不良事件发生率：对 116 名 IBD 患者进行了分析，其中包括 94 名男性（81.03%），平均年龄（39.52 ± 9.12）岁。SIBDQ、GAD-7、SQS和EQ-5D-5 L指数均有所改善（p p 结论：CBMP治疗与IBD患者不良反应的改善相关：CBMP 治疗与患者的 IBD 特异性结果和 18 个月的一般 HRQoL 改善有关。但是，还不能推断出因果关系。因此，仍需进行随机对照试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Gastroenterology & Hepatology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.80

自引率

2.60%

发文量

审稿时长

6-12 weeks

期刊介绍： The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.